Boehringer Ingelheim - Database of Clinical Trials by Pharmaceutical Companies

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Boehringer Ingelheim

Top of Directory » All Categories » by Company » Boehringer Ingelheim



  • A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

    Condition:   Asthma
    Interventions:   Drug: BI 1744 CL;   Drug: Placebo;   Drug: Respimat
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified November 2009
  • Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: linagliptin;   Drug: placebo
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Recruiting - verified November 2009
  • A Phase IIb 78-week Study in Patients on a Basal Insulin +/- Metformin and/or Sulfonylurea and Are Not at Goal to Add BI 10773 vs. Placebo

    Condition:   Diabetes Mellitus, Type 2
    Intervention:   Drug: BI 10773
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Recruiting - verified November 2009
  • BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

    Conditions:   Ovarian Neoplasms;   Peritoneal Neoplasms
    Interventions:   Drug: BIBF 1120;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified November 2009
  • Randomized, Placebo Controlled, Cross-over Study in the Enviromental Challenge Chamber to Assess Safety & Efficiacy of Three Oral Doses of BI 671800 Versus Fluticason Propionate and Montelukast in Sensitive Seasonal Allergic Rhintis Patients Out of Season

    Conditions:   Rhinitis, Allergic, Seasonal;   Asthma
    Interventions:   Drug: BI 671800 ED;   Drug: Fluticasone Propionate Nasal Spray;   Drug: Montelukast 10 mg
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified November 2009
  • Spiriva Observational Study Measuring SGRQ in Routine Medical Practice in Central & Eastern European Region

    Condition:   Chronic Obstructive Pulmonary Disease
    Intervention:  
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified October 2009
  • BIBW 2992 as a Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor [EGFR]

    Condition:   Carcinoma, Non-Small-Cell Lung
    Intervention:   Drug: BIBW 2992
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified October 2009
    • Menu
    Find Paid Clinical Trials